After a deep pullback in August and September, Amphastar is coming back in a big way. Following its early-November earnings report, the stock is up more than 20% in the last few weeks. It has reclaimed all its moving averages and is now consolidation with a pivot at $58.
Volume has dried up nicely during this consolidation which is typically a sign the stock is...
Amphastar Pharmaceuticals ( NASDAQ:AMPH ) is currently at historical resistance after reaching a new high today at $34.42. It's now above the average analyst target ($28.50 as of 3/7/2022) and insiders have sold $2.2 million in the past 2 months. Earnings on March 10th. The float is near 37 million with a 5.5% short interest. It is at "risk" for a...
